Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.39 |
| ▸ | SLC26A3 | P40879 | 6/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.33 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31026075 | 1.00 | MRGPRX4 (0.39) | MRGPRX4SLC26A3MAOBPTGER1EPHX2 | |
| SCHEMBL21438098 | 1.00 | MRGPRX4 (0.39) | MRGPRX4SLC26A3MAOBPTGER1EPHX2 | |
| SCHEMBL21437548 | 0.93 | MRGPRX4 (0.37) | MRGPRX4SLC26A3MAOBEPHX2PPARG | |
| SCHEMBL21438698 | 0.91 | CFD (0.38) | MRGPRX4SLC26A3PTGER1EPHX2 | |
| SCHEMBL25883872 | 0.90 | MRGPRX4 (0.39) | MRGPRX4SLC26A3MAOBPTGER1POLB | |
| SCHEMBL29672992 | 0.88 | MRGPRX4 (0.44) | MRGPRX4SLC26A3PTGER1PPARGPOLB | |
| SCHEMBL21438449 | 0.87 | SLC26A3 (0.35) | MRGPRX4SLC26A3POLB | |
| SCHEMBL29634143 | 0.87 | SLC26A3 (0.35) | MRGPRX4SLC26A3POLB | |
| SCHEMBL23217616 | 0.84 | CFD (0.38) | SLC26A3POLB | |
| SCHEMBL21437971 | 0.84 | MRGPRX4 (0.36) | MRGPRX4SLC26A3EPHX2PPARGPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |